flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Effects of Semaglutide on Chronic

Regular Follow-Up Scheduled visits and virtual check-ins help monitor your progress, answer questions, and make timely adjustments for your safety and satisfaction

(PubMed) Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M

Unlike Wegovy, orforglipron has fewer restrictions around timing

The insurer will give its largest segment of customers, employers with 100 workers or more, the option of retaining coverage of the drugs for weight loss by paying an extra charge in their health plans

Cardiovascular Health: Semaglutide extends beyond blood sugar control, offering potential cardiovascular benefits and reducing associated risks

By this point, many people have reached or are approaching the 8 mg to 12 mg dose range where the clinical data shows the most dramatic results